Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Researchers Identify Mechanism Behind Skin Fibrosis in Scleroderma

XTALKS VITALS NEWS

Skin Disease

As the mechanisms behind the disease are not fully understood, patients have no effective treatment options for the fibrosis responsible for tightening and hardening of the skin.

Share this!

November 3, 2016 | by Sarah Hand, M.Sc.

Patients with the autoimmune disease scleroderma, face a number of symptoms associated with fibrosis of the skin. As the mechanisms behind the disease are not fully understood, patients have no effective treatment options for the fibrosis responsible for tightening and hardening of the skin.

Severe cases of scleroderma can also affect the internal organs, including the lungs and associated blood vessels. Now, researchers at the Hospital for Special Surgery in New York City have discovered a potentially causative mechanism behind scleroderma-associated fibrosis.

Identification of this important mechanism could help future researchers develop new therapies for the disease. The research was published in the Journal of Clinical Investigation.

Using animal models of the autoimmune disease, the researchers studied the population of adipose-derived mesenchymal stromal cells (ADSCs) in the white adipose tissue just below the skin’s surface. These ADSCs have both regenerative and reparative functions, however little is known about what affects these cells’ survival in fibrotic skin.

In atrophied adipose tissue characteristic of skin fibrosis in scleroderma, the number of ADSCs was found to be diminished. The researchers postulate that the loss of ADSCs could contribute to the tissue fibrosis seen in scleroderma patients.



What’s more, those ADSCs which did survive in the fibrotic tissue were dependent on dendritic cells to stay alive. These cells release a compound known as lymphotoxin B, which supports the health of ADSCs.

When the researchers injected ADSCs into the diseased tissue along with an antibody designed to stimulate the release of lymphotoxin B, those replacement cells had better rates of survival. This therapeutic was also associated with a reduction in skin fibrosis and better skin functioning, suggesting that it could be an effective treatment option for patients with scleroderma.

“Injecting ADSCs is being tried in scleroderma; the possibility of stimulating the lymphotoxin B pathway to increase the survival of these stem cells is very exciting,” said Dr. Theresa T. Lu, study author and Associate Scientist, Autoimmunity and Inflammation Program and Pediatric Rheumatology, at the Hospital for Special Surgery. “By uncovering these mechanisms and targeting them with treatments, perhaps one day we can better treat the disease.”

Lu also believes that this therapy could be used to treat other autoimmune diseases, such as lupus and rheumatoid arthritis. “Improving ADSC therapy would be a major benefit to the field of rheumatology and to patients suffering from scleroderma.”


Keywords: Autoimmune Disease, Fibrosis, Skin Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.